Yellow Fever surveillance data analysis, Ashanti Region, Ghana, 2025
Abstract
Introduction Yellow fever is a vaccine-preventable arboviral hemorrhagic disease that remains a threat in West Africa. In 2021, Ghana reported a major outbreak in its northern and middle belts, with a 50% case fatality rate. We aimed to describe the distribution of yellow fever, determine temporal and seasonal trends, identify factors associated with laboratory confirmation, and assess the association between vaccination status and severe disease outcomes among confirmed yellow fever cases in the Ashanti Region from 2019 to 2024. Methods We conducted a secondary analysis of yellow fever SORMAS line-list data for the Ashanti Region from 2019 to 2024. We summarized distributions by person, place, and time using frequencies, proportions, and epidemic-month trends. Crude odds ratios were estimated from 2×2 tables using Fisher’s exact tests. We used multivariable logistic regression to estimate adjusted odds ratios for factors associated with laboratory confirmation. Results We analyzed 837 records; 27 were laboratory-confirmed, yielding a confirmation rate of 3.2%. The median age was 14 years (IQR: 5–26 years). Suspected reports rose from 66 in 2019 to 198 in 2024, and 23 of 27 confirmed cases were reported in 2024. In the adjusted analysis, reporting in 2024 was strongly associated with laboratory confirmation compared with 2019–2023 (aOR 29.94, 95% CI 9.20–97.46; p<0.001). Reporting during July–October was also independently associated with confirmation (aOR 6.27, 95% CI 2.48–15.85; p<0.001). No deaths, hemorrhagic syndrome, or bleeding/bruising were recorded among confirmed cases. Conclusion Yellow fever surveillance in the Ashanti Region showed an increase in suspected case reports, with a marked temporal and seasonal signal in 2024, particularly during July–October. Public health priorities include pre-season preparedness, district-level active surveillance, verification of vaccination status, targeted risk communication in districts with confirmed cases or a high suspected burden, improved data completeness, and rapid reconciliation of laboratory results.